Veeva Systems Inc.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, GEHC has a market cap of 31.98B. Regarding current trading prices, VEEV is priced at $236.95, while GEHC trades at $69.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas GEHC's P/E ratio is 14.67. In terms of profitability, VEEV's ROE is +0.13%, compared to GEHC's ROE of +0.26%. Regarding short-term risk, VEEV is less volatile compared to GEHC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, GEHCV has a market cap of 25.46B. Regarding current trading prices, VEEV is priced at $236.95, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas GEHCV's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to GEHCV's ROE of +0.26%. Regarding short-term risk, VEEV is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PMCUF has a market cap of 16.10B. Regarding current trading prices, VEEV is priced at $236.95, while PMCUF trades at $154.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PMCUF's P/E ratio is 256.92. In terms of profitability, VEEV's ROE is +0.13%, compared to PMCUF's ROE of +0.48%. Regarding short-term risk, VEEV is less volatile compared to PMCUF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, DOCS has a market cap of 11.10B. Regarding current trading prices, VEEV is priced at $236.95, while DOCS trades at $59.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas DOCS's P/E ratio is 59.18. In terms of profitability, VEEV's ROE is +0.13%, compared to DOCS's ROE of +0.21%. Regarding short-term risk, VEEV is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SGFY has a market cap of 8.93B. Regarding current trading prices, VEEV is priced at $236.95, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SGFY's P/E ratio is 70.91. In terms of profitability, VEEV's ROE is +0.13%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, VEEV is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MTHRY has a market cap of 8.84B. Regarding current trading prices, VEEV is priced at $236.95, while MTHRY trades at $6.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MTHRY's P/E ratio is 31.00. In terms of profitability, VEEV's ROE is +0.13%, compared to MTHRY's ROE of +0.09%. Regarding short-term risk, VEEV is more volatile compared to MTHRY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MTHRF has a market cap of 8.79B. Regarding current trading prices, VEEV is priced at $236.95, while MTHRF trades at $12.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MTHRF's P/E ratio is 31.59. In terms of profitability, VEEV's ROE is +0.13%, compared to MTHRF's ROE of +0.09%. Regarding short-term risk, VEEV is more volatile compared to MTHRF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HQY has a market cap of 7.82B. Regarding current trading prices, VEEV is priced at $236.95, while HQY trades at $90.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HQY's P/E ratio is 82.94. In terms of profitability, VEEV's ROE is +0.13%, compared to HQY's ROE of +0.05%. Regarding short-term risk, VEEV is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, RCM has a market cap of 6.04B. Regarding current trading prices, VEEV is priced at $236.95, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas RCM's P/E ratio is -102.21. In terms of profitability, VEEV's ROE is +0.13%, compared to RCM's ROE of -0.02%. Regarding short-term risk, VEEV is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BTSG has a market cap of 3.98B. Regarding current trading prices, VEEV is priced at $236.95, while BTSG trades at $22.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BTSG's P/E ratio is 84.52. In terms of profitability, VEEV's ROE is +0.13%, compared to BTSG's ROE of +0.03%. Regarding short-term risk, VEEV is less volatile compared to BTSG. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BTSGU has a market cap of 3.97B. Regarding current trading prices, VEEV is priced at $236.95, while BTSGU trades at $80.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BTSGU's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to BTSGU's ROE of +0.03%. Regarding short-term risk, VEEV is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ONEM has a market cap of 3.40B. Regarding current trading prices, VEEV is priced at $236.95, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ONEM's P/E ratio is -7.77. In terms of profitability, VEEV's ROE is +0.13%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, VEEV is less volatile compared to ONEM. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PRVA has a market cap of 3.04B. Regarding current trading prices, VEEV is priced at $236.95, while PRVA trades at $25.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PRVA's P/E ratio is 227.45. In terms of profitability, VEEV's ROE is +0.13%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, VEEV is less volatile compared to PRVA. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PINC has a market cap of 2.11B. Regarding current trading prices, VEEV is priced at $236.95, while PINC trades at $23.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PINC's P/E ratio is 22.62. In terms of profitability, VEEV's ROE is +0.13%, compared to PINC's ROE of -0.00%. Regarding short-term risk, VEEV is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PANHF has a market cap of 2.08B. Regarding current trading prices, VEEV is priced at $236.95, while PANHF trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PANHF's P/E ratio is 96.20. In terms of profitability, VEEV's ROE is +0.13%, compared to PANHF's ROE of -0.00%. Regarding short-term risk, VEEV is less volatile compared to PANHF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CERT has a market cap of 1.94B. Regarding current trading prices, VEEV is priced at $236.95, while CERT trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CERT's P/E ratio is -599.00. In terms of profitability, VEEV's ROE is +0.13%, compared to CERT's ROE of -0.00%. Regarding short-term risk, VEEV is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PGNY has a market cap of 1.82B. Regarding current trading prices, VEEV is priced at $236.95, while PGNY trades at $21.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PGNY's P/E ratio is 37.18. In terms of profitability, VEEV's ROE is +0.13%, compared to PGNY's ROE of +0.12%. Regarding short-term risk, VEEV is less volatile compared to PGNY. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SDGR has a market cap of 1.76B. Regarding current trading prices, VEEV is priced at $236.95, while SDGR trades at $23.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SDGR's P/E ratio is -9.30. In terms of profitability, VEEV's ROE is +0.13%, compared to SDGR's ROE of -0.40%. Regarding short-term risk, VEEV is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, WGS has a market cap of 1.69B. Regarding current trading prices, VEEV is priced at $236.95, while WGS trades at $59.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas WGS's P/E ratio is -42.55. In terms of profitability, VEEV's ROE is +0.13%, compared to WGS's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NXGN has a market cap of 1.61B. Regarding current trading prices, VEEV is priced at $236.95, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NXGN's P/E ratio is -266.00. In terms of profitability, VEEV's ROE is +0.13%, compared to NXGN's ROE of +0.03%. Regarding short-term risk, VEEV is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, GDRX has a market cap of 1.54B. Regarding current trading prices, VEEV is priced at $236.95, while GDRX trades at $4.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas GDRX's P/E ratio is 108.00. In terms of profitability, VEEV's ROE is +0.13%, compared to GDRX's ROE of +0.04%. Regarding short-term risk, VEEV is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PHR has a market cap of 1.51B. Regarding current trading prices, VEEV is priced at $236.95, while PHR trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PHR's P/E ratio is -25.11. In terms of profitability, VEEV's ROE is +0.13%, compared to PHR's ROE of -0.23%. Regarding short-term risk, VEEV is less volatile compared to PHR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, AGTI has a market cap of 1.37B. Regarding current trading prices, VEEV is priced at $236.95, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas AGTI's P/E ratio is -71.79. In terms of profitability, VEEV's ROE is +0.13%, compared to AGTI's ROE of -0.03%. Regarding short-term risk, VEEV is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CMPUY has a market cap of 1.27B. Regarding current trading prices, VEEV is priced at $236.95, while CMPUY trades at $24.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CMPUY's P/E ratio is 41.74. In terms of profitability, VEEV's ROE is +0.13%, compared to CMPUY's ROE of +0.04%. Regarding short-term risk, VEEV is less volatile compared to CMPUY. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, TDOC has a market cap of 1.25B. Regarding current trading prices, VEEV is priced at $236.95, while TDOC trades at $7.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas TDOC's P/E ratio is -1.20. In terms of profitability, VEEV's ROE is +0.13%, compared to TDOC's ROE of -0.68%. Regarding short-term risk, VEEV is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PIAHY has a market cap of 1.24B. Regarding current trading prices, VEEV is priced at $236.95, while PIAHY trades at $2.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PIAHY's P/E ratio is 114.50. In terms of profitability, VEEV's ROE is +0.13%, compared to PIAHY's ROE of -0.00%. Regarding short-term risk, VEEV is less volatile compared to PIAHY. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CMPVF has a market cap of 1.23B. Regarding current trading prices, VEEV is priced at $236.95, while CMPVF trades at $23.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CMPVF's P/E ratio is 40.43. In terms of profitability, VEEV's ROE is +0.13%, compared to CMPVF's ROE of +0.04%. Regarding short-term risk, VEEV is more volatile compared to CMPVF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, OMCL has a market cap of 1.21B. Regarding current trading prices, VEEV is priced at $236.95, while OMCL trades at $25.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas OMCL's P/E ratio is 56.04. In terms of profitability, VEEV's ROE is +0.13%, compared to OMCL's ROE of +0.01%. Regarding short-term risk, VEEV is less volatile compared to OMCL. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, TXG has a market cap of 1.08B. Regarding current trading prices, VEEV is priced at $236.95, while TXG trades at $8.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas TXG's P/E ratio is -5.77. In terms of profitability, VEEV's ROE is +0.13%, compared to TXG's ROE of -0.25%. Regarding short-term risk, VEEV is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EVH has a market cap of 1.06B. Regarding current trading prices, VEEV is priced at $236.95, while EVH trades at $9.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EVH's P/E ratio is -11.05. In terms of profitability, VEEV's ROE is +0.13%, compared to EVH's ROE of -0.06%. Regarding short-term risk, VEEV is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HSTM has a market cap of 849.82M. Regarding current trading prices, VEEV is priced at $236.95, while HSTM trades at $27.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HSTM's P/E ratio is 44.19. In terms of profitability, VEEV's ROE is +0.13%, compared to HSTM's ROE of +0.05%. Regarding short-term risk, VEEV is less volatile compared to HSTM. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CRWRF has a market cap of 849.22M. Regarding current trading prices, VEEV is priced at $236.95, while CRWRF trades at $24.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CRWRF's P/E ratio is 57.74. In terms of profitability, VEEV's ROE is +0.13%, compared to CRWRF's ROE of +0.04%. Regarding short-term risk, VEEV is more volatile compared to CRWRF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, RSLBF has a market cap of 816.36M. Regarding current trading prices, VEEV is priced at $236.95, while RSLBF trades at $22.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas RSLBF's P/E ratio is 36.89. In terms of profitability, VEEV's ROE is +0.13%, compared to RSLBF's ROE of +0.25%. Regarding short-term risk, VEEV is less volatile compared to RSLBF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SMSZF has a market cap of 727.28M. Regarding current trading prices, VEEV is priced at $236.95, while SMSZF trades at $8.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SMSZF's P/E ratio is 17.47. In terms of profitability, VEEV's ROE is +0.13%, compared to SMSZF's ROE of +0.20%. Regarding short-term risk, VEEV is more volatile compared to SMSZF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NUTX has a market cap of 667.45M. Regarding current trading prices, VEEV is priced at $236.95, while NUTX trades at $120.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NUTX's P/E ratio is 12.43. In terms of profitability, VEEV's ROE is +0.13%, compared to NUTX's ROE of +0.63%. Regarding short-term risk, VEEV is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SLP has a market cap of 647.57M. Regarding current trading prices, VEEV is priced at $236.95, while SLP trades at $32.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SLP's P/E ratio is 89.44. In terms of profitability, VEEV's ROE is +0.13%, compared to SLP's ROE of +0.04%. Regarding short-term risk, VEEV is less volatile compared to SLP. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SUSRF has a market cap of 643.95M. Regarding current trading prices, VEEV is priced at $236.95, while SUSRF trades at $12.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SUSRF's P/E ratio is 46.74. In terms of profitability, VEEV's ROE is +0.13%, compared to SUSRF's ROE of +0.03%. Regarding short-term risk, VEEV is less volatile compared to SUSRF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MPLN-WT has a market cap of 625.23M. Regarding current trading prices, VEEV is priced at $236.95, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MPLN-WT's ROE of -3.19%. Regarding short-term risk, VEEV is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ACCD has a market cap of 575.59M. Regarding current trading prices, VEEV is priced at $236.95, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ACCD's P/E ratio is -3.08. In terms of profitability, VEEV's ROE is +0.13%, compared to ACCD's ROE of -0.45%. Regarding short-term risk, VEEV is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CCLDP has a market cap of 566.58M. Regarding current trading prices, VEEV is priced at $236.95, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CCLDP's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, VEEV is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SHCR has a market cap of 531.78M. Regarding current trading prices, VEEV is priced at $236.95, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SHCR's P/E ratio is -3.76. In terms of profitability, VEEV's ROE is +0.13%, compared to SHCR's ROE of -0.29%. Regarding short-term risk, VEEV is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, VHIBF has a market cap of 457.31M. Regarding current trading prices, VEEV is priced at $236.95, while VHIBF trades at $8.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas VHIBF's P/E ratio is 211.75. In terms of profitability, VEEV's ROE is +0.13%, compared to VHIBF's ROE of +0.02%. Regarding short-term risk, VEEV is more volatile compared to VHIBF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, KSIOF has a market cap of 439.89M. Regarding current trading prices, VEEV is priced at $236.95, while KSIOF trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas KSIOF's P/E ratio is -77.67. In terms of profitability, VEEV's ROE is +0.13%, compared to KSIOF's ROE of -0.20%. Regarding short-term risk, VEEV is more volatile compared to KSIOF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, DH has a market cap of 398.38M. Regarding current trading prices, VEEV is priced at $236.95, while DH trades at $3.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas DH's P/E ratio is -1.04. In terms of profitability, VEEV's ROE is +0.13%, compared to DH's ROE of -0.67%. Regarding short-term risk, VEEV is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SLGCW has a market cap of 396.23M. Regarding current trading prices, VEEV is priced at $236.95, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, VEEV's ROE is +0.13%, compared to SLGCW's ROE of -0.09%. Regarding short-term risk, VEEV is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SLGC has a market cap of 396.23M. Regarding current trading prices, VEEV is priced at $236.95, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SLGC's P/E ratio is -3.04. In terms of profitability, VEEV's ROE is +0.13%, compared to SLGC's ROE of -0.09%. Regarding short-term risk, VEEV is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MPLN has a market cap of 374.98M. Regarding current trading prices, VEEV is priced at $236.95, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MPLN's P/E ratio is -0.23. In terms of profitability, VEEV's ROE is +0.13%, compared to MPLN's ROE of -3.19%. Regarding short-term risk, VEEV is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, TBRG has a market cap of 370.89M. Regarding current trading prices, VEEV is priced at $236.95, while TBRG trades at $24.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas TBRG's P/E ratio is -17.98. In terms of profitability, VEEV's ROE is +0.13%, compared to TBRG's ROE of -0.11%. Regarding short-term risk, VEEV is less volatile compared to TBRG. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CTEV has a market cap of 365.13M. Regarding current trading prices, VEEV is priced at $236.95, while CTEV trades at $21.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CTEV's P/E ratio is -0.21. In terms of profitability, VEEV's ROE is +0.13%, compared to CTEV's ROE of N/A. Regarding short-term risk, VEEV is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SPOK has a market cap of 338.62M. Regarding current trading prices, VEEV is priced at $236.95, while SPOK trades at $16.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SPOK's P/E ratio is 21.38. In terms of profitability, VEEV's ROE is +0.13%, compared to SPOK's ROE of +0.10%. Regarding short-term risk, VEEV is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NRC has a market cap of 295.98M. Regarding current trading prices, VEEV is priced at $236.95, while NRC trades at $12.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NRC's P/E ratio is 12.74. In terms of profitability, VEEV's ROE is +0.13%, compared to NRC's ROE of +0.71%. Regarding short-term risk, VEEV is less volatile compared to NRC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HCAT has a market cap of 287.40M. Regarding current trading prices, VEEV is priced at $236.95, while HCAT trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HCAT's P/E ratio is -3.59. In terms of profitability, VEEV's ROE is +0.13%, compared to HCAT's ROE of -0.19%. Regarding short-term risk, VEEV is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, TRHC has a market cap of 284.03M. Regarding current trading prices, VEEV is priced at $236.95, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas TRHC's P/E ratio is -4.27. In terms of profitability, VEEV's ROE is +0.13%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, VEEV is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SMDCF has a market cap of 280.87M. Regarding current trading prices, VEEV is priced at $236.95, while SMDCF trades at $17.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SMDCF's P/E ratio is -17.32. In terms of profitability, VEEV's ROE is +0.13%, compared to SMDCF's ROE of N/A. Regarding short-term risk, VEEV is more volatile compared to SMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, DLHTF has a market cap of 254.80M. Regarding current trading prices, VEEV is priced at $236.95, while DLHTF trades at $3.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas DLHTF's P/E ratio is -17.24. In terms of profitability, VEEV's ROE is +0.13%, compared to DLHTF's ROE of -0.24%. Regarding short-term risk, VEEV is more volatile compared to DLHTF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SMFR has a market cap of 246.37M. Regarding current trading prices, VEEV is priced at $236.95, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SMFR's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to SMFR's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SOPH has a market cap of 195.75M. Regarding current trading prices, VEEV is priced at $236.95, while SOPH trades at $2.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SOPH's P/E ratio is -3.08. In terms of profitability, VEEV's ROE is +0.13%, compared to SOPH's ROE of -0.54%. Regarding short-term risk, VEEV is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, VPAHF has a market cap of 188.24M. Regarding current trading prices, VEEV is priced at $236.95, while VPAHF trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas VPAHF's P/E ratio is -37.00. In terms of profitability, VEEV's ROE is +0.13%, compared to VPAHF's ROE of -0.18%. Regarding short-term risk, VEEV is more volatile compared to VPAHF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, OPRX has a market cap of 184.75M. Regarding current trading prices, VEEV is priced at $236.95, while OPRX trades at $9.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas OPRX's P/E ratio is -9.08. In terms of profitability, VEEV's ROE is +0.13%, compared to OPRX's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, COGZF has a market cap of 150.20M. Regarding current trading prices, VEEV is priced at $236.95, while COGZF trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas COGZF's P/E ratio is 22.00. In terms of profitability, VEEV's ROE is +0.13%, compared to COGZF's ROE of +0.17%. Regarding short-term risk, VEEV is more volatile compared to COGZF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EUDA has a market cap of 144.17M. Regarding current trading prices, VEEV is priced at $236.95, while EUDA trades at $3.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EUDA's P/E ratio is -7.19. In terms of profitability, VEEV's ROE is +0.13%, compared to EUDA's ROE of +3.05%. Regarding short-term risk, VEEV is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ONVVF has a market cap of 141.26M. Regarding current trading prices, VEEV is priced at $236.95, while ONVVF trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ONVVF's P/E ratio is -8.00. In terms of profitability, VEEV's ROE is +0.13%, compared to ONVVF's ROE of -0.97%. Regarding short-term risk, VEEV is less volatile compared to ONVVF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CPSI has a market cap of 133.71M. Regarding current trading prices, VEEV is priced at $236.95, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CPSI's P/E ratio is -183.80. In terms of profitability, VEEV's ROE is +0.13%, compared to CPSI's ROE of -0.03%. Regarding short-term risk, VEEV is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ACMLF has a market cap of 130.74M. Regarding current trading prices, VEEV is priced at $236.95, while ACMLF trades at $3.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ACMLF's P/E ratio is 7.14. In terms of profitability, VEEV's ROE is +0.13%, compared to ACMLF's ROE of +0.21%. Regarding short-term risk, VEEV is less volatile compared to ACMLF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, AUGX has a market cap of 115.91M. Regarding current trading prices, VEEV is priced at $236.95, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas AUGX's P/E ratio is -4.99. In terms of profitability, VEEV's ROE is +0.13%, compared to AUGX's ROE of -1.82%. Regarding short-term risk, VEEV is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SY has a market cap of 109.96M. Regarding current trading prices, VEEV is priced at $236.95, while SY trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SY's P/E ratio is -1.06. In terms of profitability, VEEV's ROE is +0.13%, compared to SY's ROE of -0.26%. Regarding short-term risk, VEEV is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, AMWL has a market cap of 108.77M. Regarding current trading prices, VEEV is priced at $236.95, while AMWL trades at $6.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas AMWL's P/E ratio is -0.68. In terms of profitability, VEEV's ROE is +0.13%, compared to AMWL's ROE of -0.48%. Regarding short-term risk, VEEV is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CSAMF has a market cap of 98.80M. Regarding current trading prices, VEEV is priced at $236.95, while CSAMF trades at $4.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CSAMF's P/E ratio is -9.64. In terms of profitability, VEEV's ROE is +0.13%, compared to CSAMF's ROE of -1.58%. Regarding short-term risk, VEEV is more volatile compared to CSAMF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CCLD has a market cap of 80.62M. Regarding current trading prices, VEEV is priced at $236.95, while CCLD trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CCLD's P/E ratio is -6.80. In terms of profitability, VEEV's ROE is +0.13%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, VEEV is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CCLDO has a market cap of 77.59M. Regarding current trading prices, VEEV is priced at $236.95, while CCLDO trades at $19.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CCLDO's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, VEEV is less volatile compared to CCLDO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MDPEF has a market cap of 61.32M. Regarding current trading prices, VEEV is priced at $236.95, while MDPEF trades at $2.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MDPEF's P/E ratio is 6.00. In terms of profitability, VEEV's ROE is +0.13%, compared to MDPEF's ROE of N/A. Regarding short-term risk, VEEV is less volatile compared to MDPEF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BEAT has a market cap of 59.69M. Regarding current trading prices, VEEV is priced at $236.95, while BEAT trades at $1.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BEAT's P/E ratio is -2.42. In terms of profitability, VEEV's ROE is +0.13%, compared to BEAT's ROE of -2.81%. Regarding short-term risk, VEEV is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, FORA has a market cap of 58.53M. Regarding current trading prices, VEEV is priced at $236.95, while FORA trades at $1.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas FORA's P/E ratio is -15.64. In terms of profitability, VEEV's ROE is +0.13%, compared to FORA's ROE of -0.14%. Regarding short-term risk, VEEV is less volatile compared to FORA. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BEATW has a market cap of 56.82M. Regarding current trading prices, VEEV is priced at $236.95, while BEATW trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BEATW's P/E ratio is -1.05. In terms of profitability, VEEV's ROE is +0.13%, compared to BEATW's ROE of -2.81%. Regarding short-term risk, VEEV is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HITC has a market cap of 52.84M. Regarding current trading prices, VEEV is priced at $236.95, while HITC trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HITC's P/E ratio is -14.75. In terms of profitability, VEEV's ROE is +0.13%, compared to HITC's ROE of -1.29%. Regarding short-term risk, VEEV is more volatile compared to HITC. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SHLT has a market cap of 41.56M. Regarding current trading prices, VEEV is priced at $236.95, while SHLT trades at $2.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SHLT's P/E ratio is -4.68. In terms of profitability, VEEV's ROE is +0.13%, compared to SHLT's ROE of -0.09%. Regarding short-term risk, VEEV is less volatile compared to SHLT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SNCE has a market cap of 34.66M. Regarding current trading prices, VEEV is priced at $236.95, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SNCE's P/E ratio is -0.27. In terms of profitability, VEEV's ROE is +0.13%, compared to SNCE's ROE of -0.59%. Regarding short-term risk, VEEV is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, AKLI has a market cap of 34.10M. Regarding current trading prices, VEEV is priced at $236.95, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas AKLI's P/E ratio is -0.71. In terms of profitability, VEEV's ROE is +0.13%, compared to AKLI's ROE of -0.74%. Regarding short-term risk, VEEV is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SHCRW has a market cap of 32.55M. Regarding current trading prices, VEEV is priced at $236.95, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to SHCRW's ROE of -0.29%. Regarding short-term risk, VEEV is less volatile compared to SHCRW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, RQHTF has a market cap of 30.03M. Regarding current trading prices, VEEV is priced at $236.95, while RQHTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas RQHTF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to RQHTF's ROE of -2.22%. Regarding short-term risk, VEEV is less volatile compared to RQHTF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, VASO has a market cap of 23.54M. Regarding current trading prices, VEEV is priced at $236.95, while VASO trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas VASO's P/E ratio is 13.40. In terms of profitability, VEEV's ROE is +0.13%, compared to VASO's ROE of +0.04%. Regarding short-term risk, VEEV is less volatile compared to VASO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, RNLX has a market cap of 22.55M. Regarding current trading prices, VEEV is priced at $236.95, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas RNLX's P/E ratio is -0.33. In terms of profitability, VEEV's ROE is +0.13%, compared to RNLX's ROE of +4.71%. Regarding short-term risk, VEEV is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, RTNXF has a market cap of 22.55M. Regarding current trading prices, VEEV is priced at $236.95, while RTNXF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas RTNXF's P/E ratio is -0.33. In terms of profitability, VEEV's ROE is +0.13%, compared to RTNXF's ROE of +4.71%. Regarding short-term risk, VEEV is less volatile compared to RTNXF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, LIFW has a market cap of 22.36M. Regarding current trading prices, VEEV is priced at $236.95, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas LIFW's P/E ratio is -0.02. In terms of profitability, VEEV's ROE is +0.13%, compared to LIFW's ROE of -0.35%. Regarding short-term risk, VEEV is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HDSLF has a market cap of 21.13M. Regarding current trading prices, VEEV is priced at $236.95, while HDSLF trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HDSLF's P/E ratio is -3.22. In terms of profitability, VEEV's ROE is +0.13%, compared to HDSLF's ROE of -1.31%. Regarding short-term risk, VEEV is more volatile compared to HDSLF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MSPR has a market cap of 19.07M. Regarding current trading prices, VEEV is priced at $236.95, while MSPR trades at $1.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MSPR's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPR's ROE of -0.35%. Regarding short-term risk, VEEV is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, VSEE has a market cap of 18.48M. Regarding current trading prices, VEEV is priced at $236.95, while VSEE trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas VSEE's P/E ratio is -14.75. In terms of profitability, VEEV's ROE is +0.13%, compared to VSEE's ROE of -6.10%. Regarding short-term risk, VEEV is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, THKKF has a market cap of 17.81M. Regarding current trading prices, VEEV is priced at $236.95, while THKKF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas THKKF's P/E ratio is -1.51. In terms of profitability, VEEV's ROE is +0.13%, compared to THKKF's ROE of -0.61%. Regarding short-term risk, VEEV is more volatile compared to THKKF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, VSEEW has a market cap of 17.74M. Regarding current trading prices, VEEV is priced at $236.95, while VSEEW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas VSEEW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to VSEEW's ROE of -6.10%. Regarding short-term risk, VEEV is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, DGNOF has a market cap of 17.65M. Regarding current trading prices, VEEV is priced at $236.95, while DGNOF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas DGNOF's P/E ratio is -5.77. In terms of profitability, VEEV's ROE is +0.13%, compared to DGNOF's ROE of +2.18%. Regarding short-term risk, VEEV is more volatile compared to DGNOF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BFRG has a market cap of 16.57M. Regarding current trading prices, VEEV is priced at $236.95, while BFRG trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BFRG's P/E ratio is -2.07. In terms of profitability, VEEV's ROE is +0.13%, compared to BFRG's ROE of -1.33%. Regarding short-term risk, VEEV is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, UDOCF has a market cap of 16.03M. Regarding current trading prices, VEEV is priced at $236.95, while UDOCF trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas UDOCF's P/E ratio is -3.50. In terms of profitability, VEEV's ROE is +0.13%, compared to UDOCF's ROE of +6.57%. Regarding short-term risk, VEEV is less volatile compared to UDOCF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, TREIF has a market cap of 15.72M. Regarding current trading prices, VEEV is priced at $236.95, while TREIF trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas TREIF's P/E ratio is -2.26. In terms of profitability, VEEV's ROE is +0.13%, compared to TREIF's ROE of -11.21%. Regarding short-term risk, VEEV is less volatile compared to TREIF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MNNDF has a market cap of 14.25M. Regarding current trading prices, VEEV is priced at $236.95, while MNNDF trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MNNDF's P/E ratio is -1.48. In terms of profitability, VEEV's ROE is +0.13%, compared to MNNDF's ROE of N/A. Regarding short-term risk, VEEV is less volatile compared to MNNDF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BBLN has a market cap of 14.10M. Regarding current trading prices, VEEV is priced at $236.95, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BBLN's P/E ratio is -0.04. In terms of profitability, VEEV's ROE is +0.13%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, VEEV is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, INOV has a market cap of 13.89M. Regarding current trading prices, VEEV is priced at $236.95, while INOV trades at $31.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas INOV's P/E ratio is 16.35. In terms of profitability, VEEV's ROE is +0.13%, compared to INOV's ROE of +0.03%. Regarding short-term risk, VEEV is more volatile compared to INOV. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, AIMLF has a market cap of 13.00M. Regarding current trading prices, VEEV is priced at $236.95, while AIMLF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas AIMLF's P/E ratio is -1.87. In terms of profitability, VEEV's ROE is +0.13%, compared to AIMLF's ROE of -11.81%. Regarding short-term risk, VEEV is more volatile compared to AIMLF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ONMD has a market cap of 12.61M. Regarding current trading prices, VEEV is priced at $236.95, while ONMD trades at $0.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ONMD's P/E ratio is -1.14. In terms of profitability, VEEV's ROE is +0.13%, compared to ONMD's ROE of +0.62%. Regarding short-term risk, VEEV is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, STRM has a market cap of 11.69M. Regarding current trading prices, VEEV is priced at $236.95, while STRM trades at $2.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas STRM's P/E ratio is -1.07. In terms of profitability, VEEV's ROE is +0.13%, compared to STRM's ROE of -0.80%. Regarding short-term risk, VEEV is less volatile compared to STRM. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CRVW has a market cap of 11.68M. Regarding current trading prices, VEEV is priced at $236.95, while CRVW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CRVW's P/E ratio is -2.00. In terms of profitability, VEEV's ROE is +0.13%, compared to CRVW's ROE of +0.12%. Regarding short-term risk, VEEV is less volatile compared to CRVW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SCNX has a market cap of 11.51M. Regarding current trading prices, VEEV is priced at $236.95, while SCNX trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SCNX's P/E ratio is -0.17. In terms of profitability, VEEV's ROE is +0.13%, compared to SCNX's ROE of +0.19%. Regarding short-term risk, VEEV is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PBSV has a market cap of 11.46M. Regarding current trading prices, VEEV is priced at $236.95, while PBSV trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PBSV's P/E ratio is -25.00. In terms of profitability, VEEV's ROE is +0.13%, compared to PBSV's ROE of -0.00%. Regarding short-term risk, VEEV is more volatile compared to PBSV. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MGRX has a market cap of 10.97M. Regarding current trading prices, VEEV is priced at $236.95, while MGRX trades at $1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MGRX's P/E ratio is -0.36. In terms of profitability, VEEV's ROE is +0.13%, compared to MGRX's ROE of -0.87%. Regarding short-term risk, VEEV is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ETAO has a market cap of 9.78M. Regarding current trading prices, VEEV is priced at $236.95, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ETAO's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, VEEV is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EMOR has a market cap of 9.66M. Regarding current trading prices, VEEV is priced at $236.95, while EMOR trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EMOR's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to EMOR's ROE of +0.28%. Regarding short-term risk, VEEV is more volatile compared to EMOR. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HSCHF has a market cap of 9.50M. Regarding current trading prices, VEEV is priced at $236.95, while HSCHF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HSCHF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to HSCHF's ROE of +0.00%. Regarding short-term risk, VEEV is more volatile compared to HSCHF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, VYND has a market cap of 9.16M. Regarding current trading prices, VEEV is priced at $236.95, while VYND trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas VYND's P/E ratio is -24.99. In terms of profitability, VEEV's ROE is +0.13%, compared to VYND's ROE of +0.38%. Regarding short-term risk, VEEV is more volatile compared to VYND. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HCTI has a market cap of 8.97M. Regarding current trading prices, VEEV is priced at $236.95, while HCTI trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HCTI's P/E ratio is -0.18. In terms of profitability, VEEV's ROE is +0.13%, compared to HCTI's ROE of +2.95%. Regarding short-term risk, VEEV is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HBCNF has a market cap of 8.44M. Regarding current trading prices, VEEV is priced at $236.95, while HBCNF trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HBCNF's P/E ratio is -0.59. In terms of profitability, VEEV's ROE is +0.13%, compared to HBCNF's ROE of -0.57%. Regarding short-term risk, VEEV is less volatile compared to HBCNF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SPLTF has a market cap of 7.95M. Regarding current trading prices, VEEV is priced at $236.95, while SPLTF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SPLTF's P/E ratio is -2.60. In terms of profitability, VEEV's ROE is +0.13%, compared to SPLTF's ROE of -6.63%. Regarding short-term risk, VEEV is less volatile compared to SPLTF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HLTH has a market cap of 6.90M. Regarding current trading prices, VEEV is priced at $236.95, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HLTH's P/E ratio is -0.02. In terms of profitability, VEEV's ROE is +0.13%, compared to HLTH's ROE of -1.04%. Regarding short-term risk, VEEV is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, OTRK has a market cap of 6.86M. Regarding current trading prices, VEEV is priced at $236.95, while OTRK trades at $1.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas OTRK's P/E ratio is -0.10. In terms of profitability, VEEV's ROE is +0.13%, compared to OTRK's ROE of -1.76%. Regarding short-term risk, VEEV is less volatile compared to OTRK. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CRBKF has a market cap of 6.84M. Regarding current trading prices, VEEV is priced at $236.95, while CRBKF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CRBKF's P/E ratio is -1.40. In terms of profitability, VEEV's ROE is +0.13%, compared to CRBKF's ROE of +68.80%. Regarding short-term risk, VEEV is more volatile compared to CRBKF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, DOCRF has a market cap of 6.25M. Regarding current trading prices, VEEV is priced at $236.95, while DOCRF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas DOCRF's P/E ratio is -0.11. In terms of profitability, VEEV's ROE is +0.13%, compared to DOCRF's ROE of -1.25%. Regarding short-term risk, VEEV is more volatile compared to DOCRF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ZCMD has a market cap of 5.93M. Regarding current trading prices, VEEV is priced at $236.95, while ZCMD trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ZCMD's P/E ratio is -9.50. In terms of profitability, VEEV's ROE is +0.13%, compared to ZCMD's ROE of -0.03%. Regarding short-term risk, VEEV is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MDBIF has a market cap of 5.50M. Regarding current trading prices, VEEV is priced at $236.95, while MDBIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MDBIF's P/E ratio is -0.21. In terms of profitability, VEEV's ROE is +0.13%, compared to MDBIF's ROE of -0.14%. Regarding short-term risk, VEEV is less volatile compared to MDBIF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, UPH has a market cap of 5.33M. Regarding current trading prices, VEEV is priced at $236.95, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas UPH's P/E ratio is -0.07. In terms of profitability, VEEV's ROE is +0.13%, compared to UPH's ROE of -0.54%. Regarding short-term risk, VEEV is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CNONF has a market cap of 4.99M. Regarding current trading prices, VEEV is priced at $236.95, while CNONF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CNONF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CNONF's ROE of +1.60%. Regarding short-term risk, VEEV is less volatile compared to CNONF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, RYAHF has a market cap of 4.96M. Regarding current trading prices, VEEV is priced at $236.95, while RYAHF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas RYAHF's P/E ratio is 0.25. In terms of profitability, VEEV's ROE is +0.13%, compared to RYAHF's ROE of +0.00%. Regarding short-term risk, VEEV is more volatile compared to RYAHF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CDXFF has a market cap of 4.87M. Regarding current trading prices, VEEV is priced at $236.95, while CDXFF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CDXFF's P/E ratio is -1.20. In terms of profitability, VEEV's ROE is +0.13%, compared to CDXFF's ROE of +0.44%. Regarding short-term risk, VEEV is less volatile compared to CDXFF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, IQAIF has a market cap of 4.19M. Regarding current trading prices, VEEV is priced at $236.95, while IQAIF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas IQAIF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to IQAIF's ROE of -2.26%. Regarding short-term risk, VEEV is less volatile compared to IQAIF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CMPD has a market cap of 4.17M. Regarding current trading prices, VEEV is priced at $236.95, while CMPD trades at $3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CMPD's P/E ratio is -16.50. In terms of profitability, VEEV's ROE is +0.13%, compared to CMPD's ROE of +0.07%. Regarding short-term risk, VEEV is less volatile compared to CMPD. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ACON has a market cap of 4.13M. Regarding current trading prices, VEEV is priced at $236.95, while ACON trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ACON's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to ACON's ROE of -3.67%. Regarding short-term risk, VEEV is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PEAR has a market cap of 4.09M. Regarding current trading prices, VEEV is priced at $236.95, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PEAR's P/E ratio is -0.08. In terms of profitability, VEEV's ROE is +0.13%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, VEEV is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PEARW has a market cap of 4.09M. Regarding current trading prices, VEEV is priced at $236.95, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PEARW's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, VEEV is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CBDS has a market cap of 3.83M. Regarding current trading prices, VEEV is priced at $236.95, while CBDS trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CBDS's P/E ratio is -1.34. In terms of profitability, VEEV's ROE is +0.13%, compared to CBDS's ROE of +1.55%. Regarding short-term risk, VEEV is less volatile compared to CBDS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EUDAW has a market cap of 3.72M. Regarding current trading prices, VEEV is priced at $236.95, while EUDAW trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EUDAW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to EUDAW's ROE of +3.05%. Regarding short-term risk, VEEV is more volatile compared to EUDAW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ICCT has a market cap of 3.69M. Regarding current trading prices, VEEV is priced at $236.95, while ICCT trades at $1.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ICCT's P/E ratio is -0.03. In terms of profitability, VEEV's ROE is +0.13%, compared to ICCT's ROE of -14.51%. Regarding short-term risk, VEEV is less volatile compared to ICCT. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MITI has a market cap of 2.99M. Regarding current trading prices, VEEV is priced at $236.95, while MITI trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MITI's P/E ratio is -0.64. In terms of profitability, VEEV's ROE is +0.13%, compared to MITI's ROE of +0.15%. Regarding short-term risk, VEEV is more volatile compared to MITI. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, FOXO has a market cap of 2.73M. Regarding current trading prices, VEEV is priced at $236.95, while FOXO trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas FOXO's P/E ratio is -0.07. In terms of profitability, VEEV's ROE is +0.13%, compared to FOXO's ROE of -0.01%. Regarding short-term risk, VEEV is less volatile compared to FOXO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CMHSF has a market cap of 2.23M. Regarding current trading prices, VEEV is priced at $236.95, while CMHSF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CMHSF's P/E ratio is 0.90. In terms of profitability, VEEV's ROE is +0.13%, compared to CMHSF's ROE of +0.10%. Regarding short-term risk, VEEV is more volatile compared to CMHSF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EKGGF has a market cap of 1.97M. Regarding current trading prices, VEEV is priced at $236.95, while EKGGF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EKGGF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to EKGGF's ROE of +0.45%. Regarding short-term risk, VEEV is less volatile compared to EKGGF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EBYH has a market cap of 1.89M. Regarding current trading prices, VEEV is priced at $236.95, while EBYH trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EBYH's P/E ratio is -5.43. In terms of profitability, VEEV's ROE is +0.13%, compared to EBYH's ROE of -0.03%. Regarding short-term risk, VEEV is more volatile compared to EBYH. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BNVIF has a market cap of 1.68M. Regarding current trading prices, VEEV is priced at $236.95, while BNVIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BNVIF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to BNVIF's ROE of -4.34%. Regarding short-term risk, VEEV is more volatile compared to BNVIF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CMAX has a market cap of 1.61M. Regarding current trading prices, VEEV is priced at $236.95, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CMAX's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to CMAX's ROE of +30.94%. Regarding short-term risk, VEEV is less volatile compared to CMAX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CSOC has a market cap of 1.60M. Regarding current trading prices, VEEV is priced at $236.95, while CSOC trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CSOC's P/E ratio is 0.29. In terms of profitability, VEEV's ROE is +0.13%, compared to CSOC's ROE of -2.38%. Regarding short-term risk, VEEV is more volatile compared to CSOC. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, WORX has a market cap of 1.41M. Regarding current trading prices, VEEV is priced at $236.95, while WORX trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas WORX's P/E ratio is -0.78. In terms of profitability, VEEV's ROE is +0.13%, compared to WORX's ROE of -0.28%. Regarding short-term risk, VEEV is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, LVCE has a market cap of 1.35M. Regarding current trading prices, VEEV is priced at $236.95, while LVCE trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas LVCE's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to LVCE's ROE of N/A. Regarding short-term risk, VEEV is more volatile compared to LVCE. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, WGSWW has a market cap of 1.30M. Regarding current trading prices, VEEV is priced at $236.95, while WGSWW trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas WGSWW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to WGSWW's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, LIFWZ has a market cap of 1.25M. Regarding current trading prices, VEEV is priced at $236.95, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to LIFWZ's ROE of -0.35%. Regarding short-term risk, VEEV is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CTVEF has a market cap of 1.22M. Regarding current trading prices, VEEV is priced at $236.95, while CTVEF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CTVEF's P/E ratio is -0.11. In terms of profitability, VEEV's ROE is +0.13%, compared to CTVEF's ROE of +0.08%. Regarding short-term risk, VEEV is more volatile compared to CTVEF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EVAHF has a market cap of 1.09M. Regarding current trading prices, VEEV is priced at $236.95, while EVAHF trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EVAHF's P/E ratio is -9.40. In terms of profitability, VEEV's ROE is +0.13%, compared to EVAHF's ROE of +0.29%. Regarding short-term risk, VEEV is less volatile compared to EVAHF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, OTRKP has a market cap of 1.01M. Regarding current trading prices, VEEV is priced at $236.95, while OTRKP trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas OTRKP's P/E ratio is -0.08. In terms of profitability, VEEV's ROE is +0.13%, compared to OTRKP's ROE of -1.76%. Regarding short-term risk, VEEV is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PPJE has a market cap of 920484.00. Regarding current trading prices, VEEV is priced at $236.95, while PPJE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PPJE's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to PPJE's ROE of +0.00%. Regarding short-term risk, VEEV is more volatile compared to PPJE. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MDXL has a market cap of 845013.00. Regarding current trading prices, VEEV is priced at $236.95, while MDXL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MDXL's P/E ratio is -0.10. In terms of profitability, VEEV's ROE is +0.13%, compared to MDXL's ROE of +0.90%. Regarding short-term risk, VEEV is less volatile compared to MDXL. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CGNSF has a market cap of 647206.00. Regarding current trading prices, VEEV is priced at $236.95, while CGNSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CGNSF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CGNSF's ROE of +0.96%. Regarding short-term risk, VEEV is less volatile compared to CGNSF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NEWUF has a market cap of 625851.00. Regarding current trading prices, VEEV is priced at $236.95, while NEWUF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NEWUF's P/E ratio is -0.02. In terms of profitability, VEEV's ROE is +0.13%, compared to NEWUF's ROE of +0.67%. Regarding short-term risk, VEEV is more volatile compared to NEWUF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ACHKF has a market cap of 522554.00. Regarding current trading prices, VEEV is priced at $236.95, while ACHKF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ACHKF's P/E ratio is -0.07. In terms of profitability, VEEV's ROE is +0.13%, compared to ACHKF's ROE of +2.16%. Regarding short-term risk, VEEV is less volatile compared to ACHKF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MDNWF has a market cap of 517288.00. Regarding current trading prices, VEEV is priced at $236.95, while MDNWF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MDNWF's P/E ratio is -0.02. In terms of profitability, VEEV's ROE is +0.13%, compared to MDNWF's ROE of -1.53%. Regarding short-term risk, VEEV is less volatile compared to MDNWF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NDATF has a market cap of 450469.00. Regarding current trading prices, VEEV is priced at $236.95, while NDATF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NDATF's P/E ratio is -0.55. In terms of profitability, VEEV's ROE is +0.13%, compared to NDATF's ROE of -0.62%. Regarding short-term risk, VEEV is more volatile compared to NDATF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MDRM has a market cap of 446418.00. Regarding current trading prices, VEEV is priced at $236.95, while MDRM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MDRM's P/E ratio is -0.35. In terms of profitability, VEEV's ROE is +0.13%, compared to MDRM's ROE of +0.42%. Regarding short-term risk, VEEV is more volatile compared to MDRM. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, DTRK has a market cap of 327488.00. Regarding current trading prices, VEEV is priced at $236.95, while DTRK trades at $0.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas DTRK's P/E ratio is -8.54. In terms of profitability, VEEV's ROE is +0.13%, compared to DTRK's ROE of -9.79%. Regarding short-term risk, VEEV is less volatile compared to DTRK. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, LFCOF has a market cap of 281984.00. Regarding current trading prices, VEEV is priced at $236.95, while LFCOF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas LFCOF's P/E ratio is -0.04. In terms of profitability, VEEV's ROE is +0.13%, compared to LFCOF's ROE of +8.70%. Regarding short-term risk, VEEV is less volatile compared to LFCOF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NMXS has a market cap of 201522.00. Regarding current trading prices, VEEV is priced at $236.95, while NMXS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NMXS's P/E ratio is -0.53. In terms of profitability, VEEV's ROE is +0.13%, compared to NMXS's ROE of +1.59%. Regarding short-term risk, VEEV is less volatile compared to NMXS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, TSTTF has a market cap of 192400.00. Regarding current trading prices, VEEV is priced at $236.95, while TSTTF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas TSTTF's P/E ratio is -0.07. In terms of profitability, VEEV's ROE is +0.13%, compared to TSTTF's ROE of +0.33%. Regarding short-term risk, VEEV is less volatile compared to TSTTF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EWLL has a market cap of 185077.00. Regarding current trading prices, VEEV is priced at $236.95, while EWLL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EWLL's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to EWLL's ROE of +0.00%. Regarding short-term risk, VEEV is less volatile compared to EWLL. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, KERN has a market cap of 162320.00. Regarding current trading prices, VEEV is priced at $236.95, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas KERN's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to KERN's ROE of +0.65%. Regarding short-term risk, VEEV is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, KERNW has a market cap of 162320.00. Regarding current trading prices, VEEV is priced at $236.95, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas KERNW's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to KERNW's ROE of +0.65%. Regarding short-term risk, VEEV is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ALDNF has a market cap of 160415.00. Regarding current trading prices, VEEV is priced at $236.95, while ALDNF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ALDNF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to ALDNF's ROE of +0.00%. Regarding short-term risk, VEEV is more volatile compared to ALDNF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, USPS has a market cap of 158503.00. Regarding current trading prices, VEEV is priced at $236.95, while USPS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas USPS's P/E ratio is -1.00. In terms of profitability, VEEV's ROE is +0.13%, compared to USPS's ROE of N/A. Regarding short-term risk, VEEV is less volatile compared to USPS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, EMYSF has a market cap of 151670.00. Regarding current trading prices, VEEV is priced at $236.95, while EMYSF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas EMYSF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to EMYSF's ROE of +0.00%. Regarding short-term risk, VEEV is less volatile compared to EMYSF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, DSOL has a market cap of 88891.00. Regarding current trading prices, VEEV is priced at $236.95, while DSOL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas DSOL's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to DSOL's ROE of +0.05%. Regarding short-term risk, VEEV is more volatile compared to DSOL. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NHIQ has a market cap of 82414.00. Regarding current trading prices, VEEV is priced at $236.95, while NHIQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NHIQ's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to NHIQ's ROE of +0.35%. Regarding short-term risk, VEEV is less volatile compared to NHIQ. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PASO has a market cap of 74059.00. Regarding current trading prices, VEEV is priced at $236.95, while PASO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PASO's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to PASO's ROE of +6.20%. Regarding short-term risk, VEEV is more volatile compared to PASO. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ICCO has a market cap of 71654.00. Regarding current trading prices, VEEV is priced at $236.95, while ICCO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ICCO's P/E ratio is -0.40. In terms of profitability, VEEV's ROE is +0.13%, compared to ICCO's ROE of +0.17%. Regarding short-term risk, VEEV is less volatile compared to ICCO. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, REFG has a market cap of 60838.00. Regarding current trading prices, VEEV is priced at $236.95, while REFG trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas REFG's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to REFG's ROE of +0.01%. Regarding short-term risk, VEEV is more volatile compared to REFG. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, LIFWW has a market cap of 60053.00. Regarding current trading prices, VEEV is priced at $236.95, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas LIFWW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to LIFWW's ROE of -0.35%. Regarding short-term risk, VEEV is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MSPRZ has a market cap of 47383.00. Regarding current trading prices, VEEV is priced at $236.95, while MSPRZ trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPRZ's ROE of -0.35%. Regarding short-term risk, VEEV is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SOFE has a market cap of 45131.00. Regarding current trading prices, VEEV is priced at $236.95, while SOFE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SOFE's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to SOFE's ROE of +0.52%. Regarding short-term risk, VEEV is less volatile compared to SOFE. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HDVY has a market cap of 41171.00. Regarding current trading prices, VEEV is priced at $236.95, while HDVY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HDVY's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to HDVY's ROE of +0.00%. Regarding short-term risk, VEEV is more volatile compared to HDVY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, IGRW has a market cap of 39815.00. Regarding current trading prices, VEEV is priced at $236.95, while IGRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas IGRW's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to IGRW's ROE of +7.88%. Regarding short-term risk, VEEV is less volatile compared to IGRW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CMAXW has a market cap of 36386.00. Regarding current trading prices, VEEV is priced at $236.95, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CMAXW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CMAXW's ROE of +30.94%. Regarding short-term risk, VEEV is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, WMGR has a market cap of 36250.00. Regarding current trading prices, VEEV is priced at $236.95, while WMGR trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas WMGR's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to WMGR's ROE of +0.00%. Regarding short-term risk, VEEV is less volatile compared to WMGR. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SSYNF has a market cap of 33293.00. Regarding current trading prices, VEEV is priced at $236.95, while SSYNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SSYNF's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to SSYNF's ROE of N/A. Regarding short-term risk, VEEV is more volatile compared to SSYNF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, RVRC has a market cap of 31411.00. Regarding current trading prices, VEEV is priced at $236.95, while RVRC trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas RVRC's P/E ratio is -0.09. In terms of profitability, VEEV's ROE is +0.13%, compared to RVRC's ROE of -0.29%. Regarding short-term risk, VEEV is less volatile compared to RVRC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, TTBLF has a market cap of 26744.00. Regarding current trading prices, VEEV is priced at $236.95, while TTBLF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas TTBLF's P/E ratio is -0.00. In terms of profitability, VEEV's ROE is +0.13%, compared to TTBLF's ROE of -1.03%. Regarding short-term risk, VEEV is less volatile compared to TTBLF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ORHB has a market cap of 25558.00. Regarding current trading prices, VEEV is priced at $236.95, while ORHB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ORHB's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to ORHB's ROE of +0.33%. Regarding short-term risk, VEEV is more volatile compared to ORHB. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ACONW has a market cap of 20907.00. Regarding current trading prices, VEEV is priced at $236.95, while ACONW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ACONW's P/E ratio is -0.01. In terms of profitability, VEEV's ROE is +0.13%, compared to ACONW's ROE of -3.67%. Regarding short-term risk, VEEV is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NHEL has a market cap of 16219.00. Regarding current trading prices, VEEV is priced at $236.95, while NHEL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NHEL's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to NHEL's ROE of +0.00%. Regarding short-term risk, VEEV is more volatile compared to NHEL. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, FDBH has a market cap of 15022.00. Regarding current trading prices, VEEV is priced at $236.95, while FDBH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas FDBH's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to FDBH's ROE of +0.32%. Regarding short-term risk, VEEV is more volatile compared to FDBH. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, HLTT has a market cap of 10663.00. Regarding current trading prices, VEEV is priced at $236.95, while HLTT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas HLTT's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to HLTT's ROE of +1789941.38%. Regarding short-term risk, VEEV is more volatile compared to HLTT. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MOSTQ has a market cap of 8517.00. Regarding current trading prices, VEEV is priced at $236.95, while MOSTQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MOSTQ's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MOSTQ's ROE of +2.26%. Regarding short-term risk, VEEV is more volatile compared to MOSTQ. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, AHGIF has a market cap of 7789.00. Regarding current trading prices, VEEV is priced at $236.95, while AHGIF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas AHGIF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to AHGIF's ROE of -2.79%. Regarding short-term risk, VEEV is less volatile compared to AHGIF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MSPRW has a market cap of 7700.00. Regarding current trading prices, VEEV is priced at $236.95, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MSPRW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPRW's ROE of -0.35%. Regarding short-term risk, VEEV is less volatile compared to MSPRW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BBLNF has a market cap of 2561.00. Regarding current trading prices, VEEV is priced at $236.95, while BBLNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BBLNF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to BBLNF's ROE of +1.06%. Regarding short-term risk, VEEV is more volatile compared to BBLNF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, PCYS has a market cap of 1105.00. Regarding current trading prices, VEEV is priced at $236.95, while PCYS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas PCYS's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to PCYS's ROE of N/A. Regarding short-term risk, VEEV is less volatile compared to PCYS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, OLMM has a market cap of 1005.00. Regarding current trading prices, VEEV is priced at $236.95, while OLMM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas OLMM's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to OLMM's ROE of +0.00%. Regarding short-term risk, VEEV is less volatile compared to OLMM. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, UTRS has a market cap of 888.00. Regarding current trading prices, VEEV is priced at $236.95, while UTRS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas UTRS's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to UTRS's ROE of -1.11%. Regarding short-term risk, VEEV is more volatile compared to UTRS. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ACNV has a market cap of 814.00. Regarding current trading prices, VEEV is priced at $236.95, while ACNV trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ACNV's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to ACNV's ROE of +0.00%. Regarding short-term risk, VEEV is less volatile compared to ACNV. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, ETAOF has a market cap of 512.00. Regarding current trading prices, VEEV is priced at $236.95, while ETAOF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas ETAOF's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to ETAOF's ROE of -13.69%. Regarding short-term risk, VEEV is less volatile compared to ETAOF. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, LGBI has a market cap of 50.00. Regarding current trading prices, VEEV is priced at $236.95, while LGBI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas LGBI's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to LGBI's ROE of +0.00%. Regarding short-term risk, VEEV is less volatile compared to LGBI. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, APYI has a market cap of 34.00. Regarding current trading prices, VEEV is priced at $236.95, while APYI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas APYI's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to APYI's ROE of -0.60%. Regarding short-term risk, VEEV is more volatile compared to APYI. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CERN comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while CERN trades at $94.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CERN's P/E ratio is 55.84. In terms of profitability, VEEV's ROE is +0.13%, compared to CERN's ROE of +0.14%. Regarding short-term risk, VEEV is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MTBC comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while MTBC trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MTBC's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, VEEV is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MTBCO comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while MTBCO trades at $25.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MTBCO's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MTBCO's ROE of +0.17%. Regarding short-term risk, VEEV is more volatile compared to MTBCO. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MSPRV comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while MSPRV trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MSPRV's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MSPRV's ROE of -0.35%. Regarding short-term risk, VEEV is less volatile compared to MSPRV. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, NH comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while NH trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas NH's P/E ratio is -0.12. In terms of profitability, VEEV's ROE is +0.13%, compared to NH's ROE of +0.35%. Regarding short-term risk, VEEV is less volatile compared to NH. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CSLT comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while CSLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CSLT's P/E ratio is -37.27. In terms of profitability, VEEV's ROE is +0.13%, compared to CSLT's ROE of -0.42%. Regarding short-term risk, VEEV is more volatile compared to CSLT. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, VMCS comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while VMCS trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas VMCS's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to VMCS's ROE of +0.08%. Regarding short-term risk, VEEV is less volatile compared to VMCS. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, SMFRW comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while SMFRW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas SMFRW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to SMFRW's ROE of -0.17%. Regarding short-term risk, VEEV is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CHNGU comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while CHNGU trades at $73.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CHNGU's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, VEEV is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CHNG comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while CHNG trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CHNG's P/E ratio is -152.72. In terms of profitability, VEEV's ROE is +0.13%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, VEEV is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, WTEQF comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while WTEQF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas WTEQF's P/E ratio is 1.78. In terms of profitability, VEEV's ROE is +0.13%, compared to WTEQF's ROE of N/A. Regarding short-term risk, VEEV is more volatile compared to WTEQF. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, MTBCP comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while MTBCP trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas MTBCP's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to MTBCP's ROE of +0.17%. Regarding short-term risk, VEEV is more volatile compared to MTBCP. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, BFRGW comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while BFRGW trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas BFRGW's P/E ratio is N/A. In terms of profitability, VEEV's ROE is +0.13%, compared to BFRGW's ROE of -1.33%. Regarding short-term risk, VEEV is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for VEEV.

VEEV plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, VEEV stands at 38.61B. In comparison, CNVY comparison data is unavailable. Regarding current trading prices, VEEV is priced at $236.95, while CNVY trades at $10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

VEEV currently has a P/E ratio of 54.98, whereas CNVY's P/E ratio is -71.50. In terms of profitability, VEEV's ROE is +0.13%, compared to CNVY's ROE of -0.02%. Regarding short-term risk, VEEV is more volatile compared to CNVY. This indicates potentially higher risk in terms of short-term price fluctuations for VEEV.